PMC Articles for PubChem Compound (Select 6918606) - PMC

Result Filters

Links from PubChem Compound

Items: 1 to 20 of 188

<< First< Prev

Page of 10

Select item 113234961.

Alternative ergosterol biosynthetic pathways confer antifungal drug resistance in the human pathogens within the Mucor species complex

María Isabel Navarro-Mendoza, Carlos Pérez-Arques, Josie Parker, Ziyan Xu, Steven Kelly, Joseph Heitman

mBio. 2024 Aug; 15(8): e01661-24. Published online 2024 Jul 9. doi: 10.1128/mbio.01661-24

PMCID:: PMC11323496

Abstract Article PDF–3.7M

Select item 112908742.

Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study

Mehmet Ergün, Anouk M E Jansen, Luuk B Hilbrands, Elizabeth de Kort, Henricus Kunst, Monique H E Reijers, Jeroen A Schouten, Paul E Verweij, Roger J M Brüggemann

J Antimicrob Chemother. 2024 Aug; 79(8): 1801–1810. Published online 2024 Apr 27. doi: 10.1093/jac/dkae139

PMCID:: PMC11290874

Abstract Article PDF–223K

Select item 112516143.

Pharmacokinetics of isavuconazonium sulfate and its active metabolite isavuconazole in healthy dogs

Erin McQuinn, Jonathan P. Mochel, David Borts, Andrew S. Hanzlicek, Karin Allenspach, Jean-Sébastien Palerme

PLoS One. 2024; 19(7): e0305766. Published online 2024 Jul 16. doi: 10.1371/journal.pone.0305766

PMCID:: PMC11251614

Abstract Article PDF–640K

Select item 111709134.

Compare the efficacy of antifungal agents as primary therapy for invasive aspergillosis: a network meta-analysis

Ao Liu, Liubo Xiong, Lian Wang, Han Zhuang, Xiao Gan, Mengying Zou, Xiaoming Wang

BMC Infect Dis. 2024; 24: 581. Published online 2024 Jun 12. doi: 10.1186/s12879-024-09477-9

PMCID:: PMC11170913

Abstract Article PDF–1.7M

Select item 110629405.

Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions

Felix Bergmann, Michael Wölfl-Duchek, Anselm Jorda, Valentin Al Jalali, Amelie Leutzendorff, Maria Sanz-Codina, Daniela Gompelmann, Karin Trimmel, Maria Weber, Sabine Eberl, Wisse Van Os, Iris K Minichmayr, Birgit Reiter, Thomas Stimpfl, Marco Idzko, Markus Zeitlinger

J Antimicrob Chemother. 2024 May; 79(5): 1169–1175. Published online 2024 Mar 28. doi: 10.1093/jac/dkae088

PMCID:: PMC11062940

Abstract Article PDF–239K

Select item 109450986.

Monitorización farmacocinética de isavuconazol en un paciente con soporte de oxigenación por membrana extracorpórea

Elena Herranz-Bayo, Rafael Huarte-Lacunza, Pilar Sánchez-Chueca, Irene Aguiló-Lafarga, Andrea Pinilla-Rello, Eva Sampedro-Calavia

Rev Esp Quimioter. 2024; 37(2): 183–185. Spanish. Published online 2024 Feb 9. doi: 10.37201/req/120.2023

PMCID:: PMC10945098

Article PDF–123K

Select item 109068917.

Economic and budgetary impact evaluation of isavuconazole (Cresemba^®) versus voriconazole (Vfend^®) for the treatment of patients with possible invasive aspergillosis from the perspective of the Brazilian supplementary health system

Gisele Lemes Veiga Araujo, Laura Murta Amaral, Vinicius Ponzio, Jaime Luis Rocha

PLoS One. 2024; 19(3): e0299056. Published online 2024 Mar 1. doi: 10.1371/journal.pone.0299056

PMCID:: PMC10906891

Abstract Article PDF–966K

Select item 108939608.

Isavuconazole in the Treatment of Chronic Forms of Coccidioidomycosis

Arash Heidari, Rupam Sharma, Qusai Shakir, Madiha Shah, Josh Clement, Monica A Donnelley, Trina Reynolds, Kate Trigg, Jeff Jolliff, Rasha Kuran, Royce Johnson, George R Thompson, III

Clin Infect Dis. 2023 Jun 15; 76(12): 2196–2199. Published online 2023 Mar 11. doi: 10.1093/cid/ciad146

PMCID:: PMC10893960

Abstract Article PDF–328K

Select item 108658049.

Trends in the activity of mold-active azole agents against Aspergillus fumigatus clinical isolates with and without cyp51 alterations from Europe and North America (2017–2021)

M. A. Pfaller, C. G. Carvalhaes, P. R. Rhomberg, L. M. Desphande, M. Castanheira

J Clin Microbiol. 2024 Feb; 62(2): e01141-23. Published online 2024 Jan 9. doi: 10.1128/jcm.01141-23

PMCID:: PMC10865804

Abstract Article PDF–363K

Select item 1076636210.

Pharmacoeconomic evaluation of isavuconazole, posaconazole, and voriconazole for the treatment of invasive mold diseases in hematological patients: initial therapy prior to pathogen differential diagnosis in China

Guangxin Han, Qing Xu, Qianzhou Lv, Xiaoyu Li, Xiaoping Shi

Front Public Health. 2023; 11: 1292162. Published online 2023 Dec 19. doi: 10.3389/fpubh.2023.1292162

PMCID:: PMC10766362

Abstract Article PDF–1.0M

Select item 1075498211.

Isavuconazole for Treating Invasive Mould Disease in Solid Organ Transplant Recipients

Jose Tiago Silva, Shahid Husain, José María Aguado

Transpl Int. 2023; 36: 11845. Published online 2023 Dec 15. doi: 10.3389/ti.2023.11845

PMCID:: PMC10754982

Abstract Article PDF–761K

Select item 1072057412.

Isavuconazole use and TDM in real-world pediatric practice

Berta Fernández Ledesma, Natalia Mendoza-Palomar, Susana Melendo Pérez, Aurora Fernández-Polo, Berta Renedo Miró, Alba Pau Parra, Sonia Luque Pardos, Santiago Grau Cerrato, Jaume Vima Bofarull, María Teresa Martín-Gómez, Montserrat Pujol Jover, Maria Isabel Benítez-Carbante, Cristina Díaz de Heredia, Pere Soler-Palacin

Antimicrob Agents Chemother. 2023 Dec; 67(12): e00829-23. Published online 2023 Nov 14. doi: 10.1128/aac.00829-23

PMCID:: PMC10720574

Abstract Article PDF–248K

Select item 1068990813.

Exploring synergy between azole antifungal drugs and statins for Candida auris

Catriona Halliday, Hannah Yejin Kim, Enoch Tay, Sharon C A Chen, Jan-Willem Alffenaar

J Antimicrob Chemother. 2023 Dec; 78(12): 2824–2829. Published online 2023 Oct 12. doi: 10.1093/jac/dkad303

PMCID:: PMC10689908

Abstract Article PDF–215K

Select item 1068461414.

High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints

Anouk M. E. Jansen, Rob ter Heine, Paul E. Verweij, Roger J. M. Brüggemann

Clin Pharmacokinet. 2023; 62(12): 1695–1699. Published online 2023 Oct 11. doi: 10.1007/s40262-023-01311-w

PMCID:: PMC10684614

Abstract Article PDF–604K

Select item 1068441815.

Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies

Anouk M. E. Jansen, Beatrijs Mertens, Isabel Spriet, Paul E. Verweij, Jeroen Schouten, Joost Wauters, Yves Debaveye, Rob ter Heine, Roger J. M. Brüggemann

Clin Pharmacokinet. 2023; 62(12): 1701–1711. Published online 2023 Oct 11. doi: 10.1007/s40262-023-01305-8

PMCID:: PMC10684418

Abstract Article PDF–1.1M

Select item 1066578216.

Evaluation of the inhibitory effect of azoles on pharmacokinetics of lenvatinib in rats both in vivo and in vitro by UPLC‐MS/MS

Mengming Xia, Xueyi Song, Zebei Lu, Yu Wang, Quan Zhou, Peiwu Geng, Shuanghu Wang, Yunfang Zhou, Qingjun Wu, Aixia Han

Thorac Cancer. 2023 Nov; 14(33): 3331–3341. Published online 2023 Sep 28. doi: 10.1111/1759-7714.15125

PMCID:: PMC10665782

Abstract Article PDF–2.1M

Select item 1058368917.

Bronchopulmonary penetration of isavuconazole in lung transplant recipients

Antonio F. Caballero-Bermejo, Ignacio Darnaude-Ximénez, Myriam Aguilar-Pérez, Alicia Gomez-Lopez, Aránzazu Sancho-López, Cristina López García-Gallo, Gema Díaz Nuevo, Elena Diago-Sempere, Belén Ruiz-Antorán, Cristina Avendaño-Solá, Piedad Ussetti-Gil, PBISA01‐Study Group

Antimicrob Agents Chemother. 2023 Oct; 67(10): e00613-23. Published online 2023 Oct 3. doi: 10.1128/aac.00613-23

PMCID:: PMC10583689

Abstract Article PDF–2.7M

Select item 1056126418.

Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review

Md. Faiyazuddin, A. Sophia, Sumel Ashique, Amol D. Gholap, S. Gowri, Sourav Mohanto, C. Karthikeyan, Sagnik Nag, Arif Hussain, Mohammad Shabib Akhtar, Md. Afroz Bakht, Mohammed Gulzar Ahmed, Sarvesh Rustagi, Alfonso J. Rodriguez-Morales, Luis Andres Salas-Matta, Aroop Mohanty, D. Katterine Bonilla-Aldana, Ranjit Sah

Front Immunol. 2023; 14: 1264502. Published online 2023 Sep 25. doi: 10.3389/fimmu.2023.1264502